Disclosure from Vaping Professionals Wanted: Exciting Rewards Await!

Industry Insight by 2FIRSTS
Jan.16.2024
Disclosure from Vaping Professionals Wanted: Exciting Rewards Await!
Rewards ranging from CN¥200 to CN¥1000 for adopted releases of information. Looking forward to your participation!

To obtain first-hand industry information, 2FIRSTS is thrilled to announce the launch of a rewarding tip-off initiative starting from January 16th. We have established a dedicated mailbox to encourage professionals within the industry to share exclusive leads in exchange for attractive rewards.

 

The information you provide can include, but is not limited to, industry dynamics, market insights, unforeseen events, company developments, and more. As long as your tip meets our requirements, 2FIRSTS will promptly assign editors to follow up, ensuring that the information receives timely attention.

 

Upon verification and adoption of the tip, the informant stands a chance to receive cash rewards ranging from ¥200 to ¥1000 (amounts may vary). In case of duplicate tips, only the first informant will be eligible for the reward.

 

Terms and Conditions:

 

Time Frame: 

Effective from January 16, 2023, ongoing.

 

Reward Mechanism: 

Cash rewards ranging from ¥200 to ¥1000 for adopted tips (only the first informant will be rewarded in case of duplicate tips).

 

Tip-off Content: 

Inclusive of, but not limited to, industry dynamics, market information, unforeseen events, company movements within the electronic cigarette industry.

 

Participation Method: 

If you are a professional in the e-cigarette industry, simply send the crucial information you possess to our dedicated email address [info@2firsts.com]. We will promptly follow up on your tip.

 

Through this interactive platform, we look forward to establishing closer connections with industry professionals and collectively driving the development of the vaping industry. We appreciate everyone's continuous support for 2FIRSTS and eagerly await your active participation in creating more enriching and accurate industry content!

 

2FIRSTS Editorial Department

 


About 2FIRSTS

 

Established in early 2022, 2FIRSTS is a globally influential aerosol technology media and think tank. Our core readership includes regulatory authorities from various countries, international new tobacco companies, distributors, supply chain enterprises, non-profit organizations, and media outlets. 2FIRSTS brings readers the latest global information, forward-thinking topics, in-depth analyses, insights, and rich data and information. We are committed to promoting high-quality development of the global new tobacco industry through media and research, contributing to harm reduction initiatives worldwide.

 

2FIRSTS has currently established platforms such as 2firsts.cn (Chinese), 2firsts.com (International), and 2firsts.com/es (Spanish), with a daily visitation exceeding 10,000.

 

With offices in Shenzhen, Hong Kong, New York, Europe, and collaborations with international new tobacco companies, regulatory authorities, and media outlets, 2FIRSTS maintains excellent cooperation and close communication. We are also proud partners and official media representatives for major global new tobacco exhibitions.

FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
The U.S. Food and Drug Administration has revised the rules under Import Alert 98-07 to incorporate its May 2026 enforcement-priority policy for certain electronic nicotine delivery systems marketed without premarket authorization. The alert continues to allow detention without physical examination, or DWPE, for ENDS lacking required marketing authorization, while directing field divisions to apply the May risk-based framework. When necessary, detention or refusal decisions must also undergo review by the FDA's Center for Tobacco Products. Products including PACHA and Vuse Pro have already emerged as industry examples of the May policy, although enforcement discretion does not constitute FDA marketing authorization.
News
Sep.28 by 2Firsts Perspectives
Elf Bar Vape Explosion and Amputation Claim Spurs Coverage Suit, U.S. Insurer MUSIC Seeks Ruling It Owes No Duty to Defend or Indemnify Distributor i5
Elf Bar Vape Explosion and Amputation Claim Spurs Coverage Suit, U.S. Insurer MUSIC Seeks Ruling It Owes No Duty to Defend or Indemnify Distributor i5
Mesa Underwriters Specialty Insurance Company has asked a federal court in Washington to declare that it has no duty to defend or indemnify vape distributor i5 Distribution in a product liability case involving an Elf Bar BC5000. The plaintiff alleges that the disposable vape caught fire and exploded in his pocket, causing severe burns and ultimately requiring an above-the-knee amputation of his left leg. MUSIC is relying on a tobacco, nicotine or nicotine replacement products exclusion and a premises limitation endorsement. The court has not ruled on the coverage dispute.
News
Sep.10
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
At the 2026 New Approaches Summit in New York, former FDA Center for Tobacco Products Director Mitch Zeller called for the tobacco harm reduction debate to shift from the traditional “end game” toward defining a desired “end state.” He also highlighted unresolved concerns around dual use, argued that biomarkers of exposure may be more meaningful than cigarettes-per-day in assessing risk reduction, and said nicotine misperceptions remain a major barrier to public health progress.
Sep.25
California Lawmakers Pass Disposable Nicotine Vape Ban, With Sales Prohibition Set for 2028
California Lawmakers Pass Disposable Nicotine Vape Ban, With Sales Prohibition Set for 2028
According to CBS Los Angeles on August 27, 2026, California lawmakers have passed Assembly Bill 762, which would phase out disposable, battery-embedded nicotine vapes in the state. If signed by Governor Gavin Newsom, manufacturing and importation of the covered products would be prohibited beginning January 1, 2027, followed by a sales ban on January 1, 2028. Driven primarily by concerns over electronic waste, lithium-battery fires and environmental pollution, the legislation would further shift California’s legal vape market toward rechargeable, refillable or replaceable-pod devices.
Aug.28
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
A federal judge in Texas on Oct. 8 granted a joint request by the FDA and plaintiffs including Altria subsidiaries Helix Innovations and NJOY to stay litigation challenging the agency's 2021 PMTA rule. The court cited FDA's anticipated rulemaking concerning the regulation at issue. FDA announced on Sept. 28 that it intends to reassess the PMTA framework and could initiate new rulemaking to replace it. The parties must file a joint status report within 45 days and every 45 days thereafter. A motion by three Reynolds American companies to intervene remains pending.
Regulations
Oct.10